A Phase 2 interventional study of ABI-007 in Metastatic Breast Cancer, sponsored by Celgene. Terminated at 14 sites in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-22.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms — 18 open to participants now, 22 under way, 2 of them phase 3. Albumin-Bound Paclitaxel · Breast Neoplasms.
Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, this one is the 23rd largest by enrollment, is one of 14 that started in 2008, is one of 67 in phase 2, and was the 19th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →18 of the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms are open now, in 10 countries. Recruiting first, the newest first:
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
Henan Cancer Hospital · Sites in China
Ages 18–70
University of Illinois at Chicago · Sites in United States
Ages 18+
Dana-Farber Cancer Institute · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 79 · Phase 3 11 · Phase 4 4
First in 2001; this study’s year is marked. 14 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 123 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 60 across the 108 interventional studies. Of the 66 that completed or were terminated, 41 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 108 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
44 studies in Breast Neoplasms by Bristol-Myers Squibb: 4 open now, 4 under way, 1 of them phase 3. Of 39 finished, 20 (51%) have results posted.
Among the 44 studies in Breast Neoplasms by Bristol-Myers Squibb, this one is the 11th largest by enrollment of the 40 interventional ones that give a count, is one of 4 that started in 2008, is one of 23 in phase 2, and was the 17th registered.
Bristol-Myers Squibb’s Breast Neoplasms studies by the year they started, since 2001.
3 of the studies testing Albumin-Bound Paclitaxel in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05420454Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study for the Neoadjuvant Treatment of Breast Cancer | 2027-06-10 |
| NCT05420467Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study for the Adjuvant Treatment of Breast Cancer | 2027-07-10 |
| NCT05287308Chinese Academy of Medical SciencesAdjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 108 studies testing Albumin-Bound Paclitaxel in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 44 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the toxicity and anti-tumor activity of nab-paclitaxel 100mg/m\^2 administered weekly in a 4-week cycle as first line therapy to patients with metastatic breast cancer who received taxanes as part of their adjuvant therapy and patients who did not receive taxanes as part of their adjuvant therapy.
This is an open-label, phase II study to determine the toxicity and antitumor activity of ABI-007 100 mg/m2 administered weekly for 3 weeks followed by a rest week (4-week cycle) as first line therapy to patients with metastatic breast cancer in the following 2 cohorts: Patients who have received a taxane as part of their adjuvant therapy, and patients who did not receive a taxane as part of their adjuvant therapy. Patients will be assessed for antitumor response every 8 weeks.
The last subject received study treatment 11DEC2012. The study was terminated on 31 May 2013 via a notification letter to all investigators on 14 May 2013.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 mg/m\^2 ABI-007 was administered by intravenous (IV) infusion over 30 minutes weekly for 3 weeks followed by 1 week rest. Therapy continued until disease progression or unacceptable toxicity.
Drug: ABI-007
100 mg/m\^2 ABI-007 weekly for 3 weeks followed by 1 week rest
Also known as: Nab-paclitaxel, Abraxane
Percentage of Participants With Objective Confirmed Complete or Partial Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 Based on Investigator and Independent Reviewers
Overall response rate (ORR) is complete response (CR) + partial response (PR). Complete response (CR): The disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. Disappearance of all non-target lesions. The normalization of tumor marker level confirmed at least 4 weeks after initial documentation. Partial response (PR): At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing. As well as persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits
Time frame: Every 8 weeks from study start until disease progression; Up to 61 months
Percentage of Participants With Disease Control
Disease control was defined as stable disease (SD) for ≥ 16 weeks or complete response (CR) or partial response (PR). Response was evaluated by the Investigator and by an independent reviewer using Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.0. See Outcome #1 for definitions of CR and PR. RECIST defines SD for target lesions as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.
Time frame: Every 8 weeks from study start until disease progression; Up to 61 months
Progression-free Survival (PFS)
PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause), whichever occurred first. Participants who did not have progression or did not die were censored at the last known time the participant was progression free. Participants who initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated.
Time frame: Study start until disease progression, death, or up to data cut off of 31 May 2013; up to 61 months
Duration of Response Based on Independent Reviewer Assessment
Duration of response was defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Participants who did not have progression or had not died were censored at the last known time the participant was progression free. Participants who had initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. CR and PR were defined in outcome #1. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST).
Time frame: Initial response until disease progression; or until data cut off 31 May 2013; up to 61 months
Duration of Response Based on Investigator Assessment
Duration of response was defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Participants who did not have progression or had not died were censored at the last known time the participant was progression free. Participants who had initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Complete response (CR) and partial response (PR) were defined in outcome #1. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST).
Time frame: Initial response until disease progression; or until data cut off 31 May 2013; up to 61 months
Patient Survival
Participant survival was the time from the first dose of study drug to participant death from any cause. Participants who did not die were censored at the last known time the participant was alive.
Time frame: Study start until death, or until data cut-off 31 May 2013; up to 61 months
Number of Participants Experiencing Dose Reductions, Interruptions, or Dose Delays of Study Drug
The number of participants with dose reductions, dose interruptions and dose delays that occurred during the treatment period. Dose reductions, interruptions and delays are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.
Time frame: Day 1 of study drug to Day 940; data cut off 31 May 2013
Number of Participants With Treatment-Emergent Adverse Events
Count of study participants who had at least one treatment-emergent adverse event (TEAE) defined as any adverse event that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity: severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE. Severity grade 5 = death.
Time frame: Day 1 to Day 940
| Milestone | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) |
|---|---|---|
| Started | 47 | 76 |
| Completed | 31 | 48 |
| Not completed | 16 | 28 |
| Withdrew: Adverse event | 2 | 15 |
| Withdrew: Physician decision | 11 | 6 |
| Withdrew: Protocol deviation | 2 | 0 |
| Withdrew: Participant discretion | 1 | 5 |
| Withdrew: Other | 0 | 2 |
Overall response rate (ORR) is complete response (CR) + partial response (PR). Complete response (CR): The disappearance of all known disease and no new sites or disease related symptoms confirmed at least 4 weeks after initial documentation. All sites must be assessed, including non-measurable sites, such as effusions, or markers. Disappearance of all non-target lesions. The normalization of tumor marker level confirmed at least 4 weeks after initial documentation. Partial response (PR): At least a 30% decrease in the sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 4 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing. As well as persistence of one or more non-target lesion(s) and/or the maintenance of tumor marker level above the normal limits
| percentage of participants | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) |
|---|---|---|
| Investigator Assessment | 30 (16.7 to 42.9) | 28 (17.6 to 37.7) |
| Independent Reviewer Assessment | 32 (18.6 to 45.2) | 32 (21.1 to 42.0) |
Disease control was defined as stable disease (SD) for ≥ 16 weeks or complete response (CR) or partial response (PR). Response was evaluated by the Investigator and by an independent reviewer using Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.0. See Outcome #1 for definitions of CR and PR. RECIST defines SD for target lesions as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions.
| percentage of participants | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) |
|---|---|---|
| Investigator Assessment | 51 (36.8 to 65.4) | 57 (45.4 to 67.7) |
| Independent Reviewer Assessment | 55 (41.1 to 69.5) | 57 (45.4 to 67.7) |
PFS was defined as the time from the first dose of study drug to the start of progression or patient death (any cause), whichever occurred first. Participants who did not have progression or did not die were censored at the last known time the participant was progression free. Participants who initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated.
| months | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) |
|---|---|---|
| Investigator Assessment | 6.0 (3.5 to 8.8) | 6.7 (5.3 to 7.3) |
| Independent Reviewer Assessment | 5.3 (3.3 to 7.3) | 5.3 (3.5 to 6.6) |
Duration of response was defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Participants who did not have progression or had not died were censored at the last known time the participant was progression free. Participants who had initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. CR and PR were defined in outcome #1. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST).
| months | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) |
|---|---|---|
| Duration of Response Based on Independent Reviewer Assessment | 10.9 (7.3 to 18.9) | 9.2 (7.4 to 14.2) |
Duration of response was defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Participants who did not have progression or had not died were censored at the last known time the participant was progression free. Participants who had initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Complete response (CR) and partial response (PR) were defined in outcome #1. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST).
| months | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) |
|---|---|---|
| Duration of Response Based on Investigator Assessment | 10.5 (8.8 to 25.4) | 10.8 (8.7 to 22.4) |
Participant survival was the time from the first dose of study drug to participant death from any cause. Participants who did not die were censored at the last known time the participant was alive.
| months | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) |
|---|---|---|
| Patient Survival | 20.9 (14.3 to 28.0) | 20.0 (13.8 to 28.6) |
The number of participants with dose reductions, dose interruptions and dose delays that occurred during the treatment period. Dose reductions, interruptions and delays are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.
| participants | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) |
|---|---|---|
| Patients with at Least One Dose Reduction | 11 | 19 |
| Patients with at Least One Dose Interruption | 3 | 2 |
| Patients with at Least One Dose Delay/Not Given | 20 | 39 |
Count of study participants who had at least one treatment-emergent adverse event (TEAE) defined as any adverse event that began or worsened in grade after the start of study drug through 30 days after the last dose of study drug. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity: severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE. Severity grade 5 = death.
| participants | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) |
|---|---|---|
| ≥1 Adverse Event (AE) | 46 | 75 |
| ≥1 Treatment related Adverse Event | 41 | 74 |
| ≥ 1 Serious Adverse Event | 5 | 14 |
| Treatment related Serious Adverse Event | 2 | 7 |
| ≥1 One Grade 3/4 Adverse Event | 25 | 36 |
| ≥1 One Grade 3 or Higher Adverse Event | 25 | 36 |
| ≥1 AE leading to treatment discontinuation | 2 | 16 |
| ≥1 AE leading to death | 0 | 2 |
| ≥1 AE leading to dose reduction of study drug | 11 | 18 |
| ≥1 AE leading to dose interruption of study drug | 2 | 0 |
| ≥1 AE leading to dose delay of study drug | 15 | 29 |
Collected over Any Adverse Event (AE) that started after initial study drug administration through the end of the study or 30 days after the last treatment, whichever was later, were followed until the AE had resolved or stabilized. Upt to 61 months.. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abraxane (Prior Taxane Therapy) | — | 5/47 (10.6%) | 46/47 (97.9%) |
| Abraxane (No Prior Taxane Therapy) | — | 14/76 (18.4%) | 75/76 (98.7%) |
| Event | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) |
|---|---|---|
| PneumoniaInfections and infestations | 0/47 | 3/76 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/47 | 2/76 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/47 | 2/76 |
| BacteraemiaInfections and infestations | 1/47 | 0/76 |
| CellulitisInfections and infestations | 1/47 | 0/76 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/47 | 0/76 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/47 | 0/76 |
| Pericardial effusionCardiac disorders | 1/47 | 0/76 |
| DiarrhoeaGastrointestinal disorders | 1/47 | 0/76 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 1/47 | 0/76 |
| Event | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 29/47 | 61/76 |
| FatigueGeneral disorders | 33/47 | 55/76 |
| NauseaGastrointestinal disorders | 24/47 | 47/76 |
| Peripheral sensory neuropathyNervous system disorders | 22/47 | 44/76 |
| DiarrhoeaGastrointestinal disorders | 15/47 | 37/76 |
| Decreased appetiteMetabolism and nutrition disorders | 16/47 | 30/76 |
| HeadacheNervous system disorders | 17/47 | 20/76 |
| ConstipationGastrointestinal disorders | 15/47 | 15/76 |
| MyalgiaMusculoskeletal and connective tissue disorders | 15/47 | 13/76 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 14/47 | 15/76 |
Treated Population
| Age, Continuous(years) | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) | Total |
|---|---|---|---|
| Mean | 55.3 ± 9.78 | 58.3 ± 10.88 | 57.2 ± 10.54 |
| Sex: Female, Male(Participants) | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) | Total |
|---|---|---|---|
| Female | 47 | 76 | 123 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) | Total |
|---|---|---|---|
| Asian | 0 | 5 | 5 |
| Black, of African Heritage | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| White, Non-Hispanic/Non Latino | 41 | 60 | 101 |
| White, Hispanic or Latino | 0 | 5 | 5 |
| Other-Unspecified | 3 | 3 | 6 |
| Menopausal Status(participants) | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) | Total |
|---|---|---|---|
| Premenopausal | 12 | 12 | 24 |
| Postmenopausal | 35 | 64 | 99 |
| Stage at Primary Diagnosis(participants) | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) | Total |
|---|---|---|---|
| Stage I | 4 | 12 | 16 |
| Stage IIa | 7 | 12 | 19 |
| Stage IIb | 14 | 13 | 27 |
| Stage IIIa | 11 | 8 | 19 |
| Stage IIIb | 6 | 4 | 10 |
| Stage IIIc | 5 | 5 | 10 |
| Stage IV | 0 | 19 | 19 |
| Unknown | 0 | 3 | 3 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) | Total |
|---|---|---|---|
| 0 (fully active) | 21 | 38 | 59 |
| 1 (restrictive but ambulatory) | 22 | 30 | 52 |
| 2 (ambulatory but unable to work) | 4 | 8 | 12 |
| 3 (limited self-care) + 4 (completely disabled) | 0 | 0 | 0 |
| Physician Assessment of Peripheral Neuropathy] [2](participants) | Abraxane (Prior Taxane Therapy) | Abraxane (No Prior Taxane Therapy) | Total |
|---|---|---|---|
| Grade 0 | 37 | 69 | 106 |
| Grade 1 | 10 | 7 | 17 |
Ran from Feb 2008 to primary completion in Dec 2012, 58 months.
Results were first posted in Jul 2014, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumin-Bound Paclitaxel